CLSD - クリアサイド・バイオメディカル (Clearside Biomedical Inc.) クリアサイド・バイオメディカル

 CLSDのチャート


 CLSDの企業情報

symbol CLSD
会社名 Clearside Biomedical Inc (クリアサイド・バイオメディカル)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 クリアサイド・バイオメディカル(Clearside Biomedical Inc.)は目のまばゆい病気を治療するための業界初の薬物療法を開発している臨床生物医薬品会社である。同社の製品候補は、網膜に影響を及ぼす病気に重点を置く。網膜は、目の内部を覆う組織であり、主に視力の原因である。網膜に隣接する層である脈絡膜は、網膜に血液、酸素、栄養を供給する。そのマイクロインジェクターでは、脈絡膜と強膜と呼ばれる眼の外側保護層との間に位置する脈絡膜上腔(SCS)内に薬物が注入されて広がる。脈絡膜上皮の注射では、眼の中心部を占めるゼリー様物質である硝子体への薬物の注射など、他の眼内薬物投与技術と比較して、その脈絡膜の生成物候補が網膜および脈絡膜に直接的に投与される。   クリアサイド・バイオメディカルは米国のバイオ医薬品企業。後期臨床段階で、主に眼科疾患のための薬物送達技術の開発に焦点を当てる。同社の登録商標製品である「SCSマイクロインジェクタ―」は網膜と、黄斑浮腫を伴う病気に関連する脈絡膜を治療するために使用される。本社はジョ―ジア州アルファレッタ。   Clearside Biomedical, Inc. is a clinical stage biopharmaceutical company, which engages in the development of drug therapies to treat blinding diseases of the eye. Its pipeline includes Suprachoroidal CLS-TA, Suprachoroidal, Suprachoroidal CLS-TA, and gene therapy. The company was founded by Samir Kumar Patel, Vladimir Zarnitsyn, Mark Prausnitz, Daniel H. White, and Henry F. Edelhauser in May 2011 and is headquartered in Alpharetta, GA.
本社所在地 900 North Point Parkway Suite 200 Alpharetta GA 30005 USA
代表者氏名 Christy L. Shaffer Christy L. Shaffer
代表者役職名 Chairman of the Board 取締役会会長
電話番号 +1 678-270-3631
設立年月日 40664
市場名 NASDAQ National Market System
ipoyear 2016年
従業員数
url www.clearsidebio.com
nasdaq_url https://www.nasdaq.com/symbol/clsd
adr_tso
EBITDA EBITDA(百万ドル) -71.68200
終値(lastsale) 5.8001
時価総額(marketcap) 185743695.8223
時価総額 時価総額(百万ドル) 185.10000
売上高 売上高(百万ドル) 0.21000
企業価値(EV) 企業価値(EV)(百万ドル) 110.51800
当期純利益 当期純利益(百万ドル) -72.13700
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Clearside Biomedical Inc revenues decreased from $135K to $0K. Net loss increased 55% to $37.3M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Research and development - Balancing val increase of 62% to $29.8M (expense) General and administrative increase of 27% to $5.2M (expense).

 CLSDのテクニカル分析


 CLSDのニュース

   Clearside Biomedical, Inc. (CLSD) Expected to Beat Earnings Estimates: Can the Stock Move Higher?  2020/03/04 17:30:31 Zacks Investment Research
Clearside Biomedical, Inc. (CLSD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
   The Daily Biotech Pulse: EyePoint In-Licenses Eye Disorder Drug, BioMarin CFO Quits, Rockwell Medical To Offer Shares  2020/02/04 12:51:48 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs Feb. 3.) Acceleron Pharma Inc (NASDAQ: XLRN ) Aptose Biosciences Inc (NASDAQ: APTO ) Catalent Inc (NYSE: CTLT ) ( announced a deal to buy cell and gene therapy CDMO MasTherCell and forecast-beating second quarter results) ChemoCentryx Inc (NASDAQ: CCXI ) Clearside Biomedical Inc (NASDAQ: CLSD ) Fate Therapeutics Inc (NASDAQ: FATE ) ITAMAR MED LTD/S ADR (NASDAQ: ITMR ) Molecular Templates Inc (NASDAQ: MTEM ) Orgenesis Inc (NASDAQ: ORGS ) (announced sale of subsidiary MasTherCell to Catalent) Profound Medical Corp (NASDAQ: PROF ) Reata Pharmaceuticals Inc (NASDAQ: RETA ) Repligen Corporation (NASDAQ: RGEN ) Theravance Biopharma Inc (NASDAQ: TBPH ) Down In The Dumps (Biotech stocks that hit 52-week lows Feb. 3.) Alkermes Plc (NASDAQ: ALKS ) Allogene Therapeutics Inc (NASDAQ: ALLO ) Avanos Medical Inc (NYSE: AVNS ) BioLife Solutions Inc (NASDAQ: BLFS ) Blueprint Medicines Corp (NASDAQ: BPMC ) CASI Pharmaceuticals Inc (NASDAQ: CASI ) (moved along with China pharmaceutical stocks due to coronavirus) Endologix, Inc. (NASDAQ: ELGX ) Galectin Therapeutics Inc. (NASDAQ: GALT ) I-Mab (NASDAQ: IMAB ) (went public in mid-January) Intec Pharma Ltd (NASDAQ: NTEC ) TapImmune Inc. (NASDAQ: MRKR ) Omeros Corporation (NASDAQ: OMER ) REDHILL BIOPHAR/S ADR (NASDAQ: RDHL ) Salarius Pharmaceuticals Inc (NASDAQ: SLRX ) X4 …
   Bausch Health and Clearside Biomedical Announce Publication of PIVOTAL Phase 3 Data ON XIPERETM (triamcinolone acetonide suprachoroidal injectable suspension) in Ophthalmology  2020/01/28 12:00:00 PR Newswire
LAVAL, Quebec and ALPHARETTA, Ga., Jan. 28, 2020 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health") and Bausch + Lomb, its leading global eye health business, and Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company dedicated to developing and…
   The Daily Biotech Pulse: Qiagen Opts To Stay Solo Following Strategic Review, Spectrum Slumps On Negative Data, Microbot Medical To Offer Shares  2019/12/26 12:55:50 Benzinga
The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs Dec. 24.) Aimmune Therapeutics Inc (NASDAQ: AIMT ) Applied Genetic Technologies Corp (NASDAQ: AGTC ) Cassava Sciences Inc (NASDAQ: SAVA ) ChemoCentryx Inc (NASDAQ: CCXI ) Clearside Biomedical Inc (NASDAQ: CLSD ) DURECT Corporation (NASDAQ: DRRX ) Eiger Biopharmaceuticals Inc (NASDAQ: EIGR ) Esperion Therapeutics Inc (NASDAQ: ESPR ) Exagen Inc (NASDAQ: XGN ) Forty Seven Inc (NASDAQ: FTSV ) Fulcrum Therapeutics Inc (NASDAQ: FULC ) Global Blood Therapeutics Inc (NASDAQ: GBT ) Harpoon Therapeutics Inc (NASDAQ: HARP ) Horizon Therapeutics PLC (NASDAQ: HZNP ) HEALTH SCIENCES/SH (NASDAQ: IMVT ) Intuitive Surgical, Inc. (NASDAQ: ISRG ) Jazz Pharmaceuticals PLC (NASDAQ: JAZZ ) Karyopharm Therapeutics Inc (NASDAQ: KPTI ) Kodiak Sciences Inc (NASDAQ: KOD ) (JPMorgan initiated coverage with an Outperform rating) Microbot Medical Inc (NASDAQ: MBOT ) Mirati Therapeutics Inc (NASDAQ: MRTX ) Momenta Pharmaceuticals, Inc.
   The Daily Biotech Pulse: Axovant Surges On Gene Therapy Study Results, FDA Approves Merck's Ebola Vaccine, Abeona Announces Offering  2019/12/20 13:12:05 Benzinga
The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs Dec. 19.) Acceleron Pharma Inc (NASDAQ: XLRN ) Ardelyx Inc (NASDAQ: ARDX ) AstraZeneca plc (NYSE: AZN ) Axsome Therapeutics Inc (NASDAQ: AXSM ) (priced its 2-million-share common stock offering at $87 per share) Clearside Biomedical Inc (NASDAQ: CLSD ) Cortexyme Inc (NASDAQ: CRTX ) Cue Biopharma Inc (NASDAQ: CUE ) Exagen Inc (NASDAQ: XGN ) Globus Medical Inc (NYSE: GMED ) Horizon Therapeutics PLC (NASDAQ: HZNP ) HEALTH SCIENCES/SH (NASDAQ: IMVT ) (The acquisition vehicle announced merger with Immuvant, a clinical-stage biopharma company focusing on autoimmune disorders) IVERIC bio Inc (NASDAQ: ISEE ) Johnson & Johnson (NYSE: JNJ ) (Barclays upgraded shares to Overweight) The Medicines Company (NASDAQ: MDCO ) Merck & Co., Inc. (NYSE: MRK ) Mirum Pharmaceuticals Inc (NASDAQ: MIRM ) Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA ) Monopar Therapeutics Inc. (NASDAQ: MNPR ) (Went public Thursday) Myokardia Inc (NASDAQ: MYOK ) NeoGenomics, Inc. (NASDAQ: NEO ) Novan Inc (NASDAQ: NOVN ) Oramed Pharmaceuticals, Inc. (NASDAQ: ORMP ) Principia Biopharma Inc (NASDAQ: PRNB ) Quest Diagnostics Inc (NYSE: DGX ) Recro Pharma Inc (NASDAQ: REPH ) Sanofi SA (NASDAQ: SNY ) SpringWorks Therapeutics Inc (NASDAQ: SWTX ) Down In The Dumps (Biotech stocks that hit 52-week lows Dec. 19.) Aethlon Medical, Inc. (NASDAQ: AEMD ) Anixa Biosciences Inc (NASDAQ: ANIX ) Aridis Pharmaceuticals Inc (NASDAQ: ARDS ) China SXT Pharmaceuticals Inc (NASDAQ: SXTC ) Correvio Pharma Corp (NASDAQ: …
   The Daily Biotech Pulse: EyePoint In-Licenses Eye Disorder Drug, BioMarin CFO Quits, Rockwell Medical To Offer Shares  2020/02/04 12:51:48 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs Feb. 3.) Acceleron Pharma Inc (NASDAQ: XLRN ) Aptose Biosciences Inc (NASDAQ: APTO ) Catalent Inc (NYSE: CTLT ) ( announced a deal to buy cell and gene therapy CDMO MasTherCell and forecast-beating second quarter results) ChemoCentryx Inc (NASDAQ: CCXI ) Clearside Biomedical Inc (NASDAQ: CLSD ) Fate Therapeutics Inc (NASDAQ: FATE ) ITAMAR MED LTD/S ADR (NASDAQ: ITMR ) Molecular Templates Inc (NASDAQ: MTEM ) Orgenesis Inc (NASDAQ: ORGS ) (announced sale of subsidiary MasTherCell to Catalent) Profound Medical Corp (NASDAQ: PROF ) Reata Pharmaceuticals Inc (NASDAQ: RETA ) Repligen Corporation (NASDAQ: RGEN ) Theravance Biopharma Inc (NASDAQ: TBPH ) Down In The Dumps (Biotech stocks that hit 52-week lows Feb. 3.) Alkermes Plc (NASDAQ: ALKS ) Allogene Therapeutics Inc (NASDAQ: ALLO ) Avanos Medical Inc (NYSE: AVNS ) BioLife Solutions Inc (NASDAQ: BLFS ) Blueprint Medicines Corp (NASDAQ: BPMC ) CASI Pharmaceuticals Inc (NASDAQ: CASI ) (moved along with China pharmaceutical stocks due to coronavirus) Endologix, Inc. (NASDAQ: ELGX ) Galectin Therapeutics Inc. (NASDAQ: GALT ) I-Mab (NASDAQ: IMAB ) (went public in mid-January) Intec Pharma Ltd (NASDAQ: NTEC ) TapImmune Inc. (NASDAQ: MRKR ) Omeros Corporation (NASDAQ: OMER ) REDHILL BIOPHAR/S ADR (NASDAQ: RDHL ) Salarius Pharmaceuticals Inc (NASDAQ: SLRX ) X4 …
   Bausch Health and Clearside Biomedical Announce Publication of PIVOTAL Phase 3 Data ON XIPERETM (triamcinolone acetonide suprachoroidal injectable suspension) in Ophthalmology  2020/01/28 12:00:00 PR Newswire
LAVAL, Quebec and ALPHARETTA, Ga., Jan. 28, 2020 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health") and Bausch + Lomb, its leading global eye health business, and Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company dedicated to developing and…
   The Daily Biotech Pulse: Qiagen Opts To Stay Solo Following Strategic Review, Spectrum Slumps On Negative Data, Microbot Medical To Offer Shares  2019/12/26 12:55:50 Benzinga
The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs Dec. 24.) Aimmune Therapeutics Inc (NASDAQ: AIMT ) Applied Genetic Technologies Corp (NASDAQ: AGTC ) Cassava Sciences Inc (NASDAQ: SAVA ) ChemoCentryx Inc (NASDAQ: CCXI ) Clearside Biomedical Inc (NASDAQ: CLSD ) DURECT Corporation (NASDAQ: DRRX ) Eiger Biopharmaceuticals Inc (NASDAQ: EIGR ) Esperion Therapeutics Inc (NASDAQ: ESPR ) Exagen Inc (NASDAQ: XGN ) Forty Seven Inc (NASDAQ: FTSV ) Fulcrum Therapeutics Inc (NASDAQ: FULC ) Global Blood Therapeutics Inc (NASDAQ: GBT ) Harpoon Therapeutics Inc (NASDAQ: HARP ) Horizon Therapeutics PLC (NASDAQ: HZNP ) HEALTH SCIENCES/SH (NASDAQ: IMVT ) Intuitive Surgical, Inc. (NASDAQ: ISRG ) Jazz Pharmaceuticals PLC (NASDAQ: JAZZ ) Karyopharm Therapeutics Inc (NASDAQ: KPTI ) Kodiak Sciences Inc (NASDAQ: KOD ) (JPMorgan initiated coverage with an Outperform rating) Microbot Medical Inc (NASDAQ: MBOT ) Mirati Therapeutics Inc (NASDAQ: MRTX ) Momenta Pharmaceuticals, Inc.
   The Daily Biotech Pulse: Axovant Surges On Gene Therapy Study Results, FDA Approves Merck's Ebola Vaccine, Abeona Announces Offering  2019/12/20 13:12:05 Benzinga
The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs Dec. 19.) Acceleron Pharma Inc (NASDAQ: XLRN ) Ardelyx Inc (NASDAQ: ARDX ) AstraZeneca plc (NYSE: AZN ) Axsome Therapeutics Inc (NASDAQ: AXSM ) (priced its 2-million-share common stock offering at $87 per share) Clearside Biomedical Inc (NASDAQ: CLSD ) Cortexyme Inc (NASDAQ: CRTX ) Cue Biopharma Inc (NASDAQ: CUE ) Exagen Inc (NASDAQ: XGN ) Globus Medical Inc (NYSE: GMED ) Horizon Therapeutics PLC (NASDAQ: HZNP ) HEALTH SCIENCES/SH (NASDAQ: IMVT ) (The acquisition vehicle announced merger with Immuvant, a clinical-stage biopharma company focusing on autoimmune disorders) IVERIC bio Inc (NASDAQ: ISEE ) Johnson & Johnson (NYSE: JNJ ) (Barclays upgraded shares to Overweight) The Medicines Company (NASDAQ: MDCO ) Merck & Co., Inc. (NYSE: MRK ) Mirum Pharmaceuticals Inc (NASDAQ: MIRM ) Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA ) Monopar Therapeutics Inc. (NASDAQ: MNPR ) (Went public Thursday) Myokardia Inc (NASDAQ: MYOK ) NeoGenomics, Inc. (NASDAQ: NEO ) Novan Inc (NASDAQ: NOVN ) Oramed Pharmaceuticals, Inc. (NASDAQ: ORMP ) Principia Biopharma Inc (NASDAQ: PRNB ) Quest Diagnostics Inc (NYSE: DGX ) Recro Pharma Inc (NASDAQ: REPH ) Sanofi SA (NASDAQ: SNY ) SpringWorks Therapeutics Inc (NASDAQ: SWTX ) Down In The Dumps (Biotech stocks that hit 52-week lows Dec. 19.) Aethlon Medical, Inc. (NASDAQ: AEMD ) Anixa Biosciences Inc (NASDAQ: ANIX ) Aridis Pharmaceuticals Inc (NASDAQ: ARDS ) China SXT Pharmaceuticals Inc (NASDAQ: SXTC ) Correvio Pharma Corp (NASDAQ: …
   Clearside Biomedical Shares Rebound On Microinjector Licensing Deal With Regenxbio  2019/09/04 14:20:28 Benzinga
Clearside Biomedical Inc (NASDAQ: CLSD ) shares — which came under intense selling pressure in late August after the company hinted at a possible FDA rejection of the NDA for its macular edema drug — got a reprieve Wednesday. What Happened Clearside announced an option and license agreement with Regenxbio Inc (NASDAQ: RGNX ), granting the latter worldwide rights to its proprietary in-office SCS Microinjector for the delivery of RGX-314 to the suprachoroidal space to treat wet age-related macular degeneration, or AMD; diabetic retinopathy, or DR; and other conditions for which anti-vascular endothelial growth factor treatment … Full story available on Benzinga.com
  クリアサイドバイオメディカルシェアは、Regenxbioとのマイクロインジェクターライセンス契約で反発 Clearside Biomedical Shares Rebound On Microinjector Licensing Deal With Regenxbio  2019/09/04 14:20:28 Benzinga
「Clearside Biomedical Inc(NASDAQ:CLSD)株-黄斑浮腫薬に対するNDAのFDA拒否の可能性を示唆した後、8月下旬に激しい販売圧力を受けた水曜日に猶予が与えられました。 Regenxbio Inc(NASDAQ:RGNX)とのライセンス契約により、加湿性加齢黄斑変性症またはAMDの治療のために脈絡膜上腔にRGX-314を送達する独自の社内SCSマイクロインジェクターの世界的な権利を後者に付与し、またはDR;および抗血管内皮増殖因子治療のその他の条件…Benzinga.comで利用可能な全容
Clearside Biomedical Inc (NASDAQ: CLSD ) shares — which came under intense selling pressure in late August after the company hinted at a possible FDA rejection of the NDA for its macular edema drug — got a reprieve Wednesday. What Happened Clearside announced an option and license agreement with Regenxbio Inc (NASDAQ: RGNX ), granting the latter worldwide rights to its proprietary in-office SCS Microinjector for the delivery of RGX-314 to the suprachoroidal space to treat wet age-related macular degeneration, or AMD; diabetic retinopathy, or DR; and other conditions for which anti-vascular endothelial growth factor treatment … Full story available on Benzinga.com
   The Daily Biotech Pulse: EC Nod For Bristol-Myers Squibb, Kyowa Kirin's Parkinson's Add-On Therapy Approved  2019/08/28 11:31:33 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Aug. 27) Castle Biosciences Inc (NASDAQ: CSTL ) The Medicines Company (NASDAQ: MDCO ) Down In The Dumps (Biotech stocks hitting 52-week lows on Aug. 27) Abeona Therapeutics Inc (NASDAQ: ABEO ) Advaxis, Inc. (NASDAQ: ADXS ) Agios Pharmaceuticals Inc (NASDAQ: AGIO ) Alder Biopharmaceuticals Inc (NASDAQ: ALDR ) Aldeyra Therapeutics Inc (NASDAQ: ALDX ) Alimera Sciences Inc (NASDAQ: ALIM ) AnaptysBio Inc (NASDAQ: ANAB ) ASLAN PHARMACEU/ADR (NASDAQ: ASLN ) Assembly Biosciences Inc (NASDAQ: ASMB ) Cancer Genetics Inc (NASDAQ: CGIX ) Catalyst Biosciences Inc (NASDAQ: CBIO ) Clearside Biomedical Inc (NASDAQ: CLSD ) Crinetics Pharmaceuticals Inc (NASDAQ: CRNX ) DelMar Pharmaceuticals Inc (NASDAQ: DMPI )(announced that its current cash position will be sufficient to complete enrollment in all three patient groups of its two ongoing Phase 2 trials for its lead compound VAL-083, which is likely to occur by the fourth quarter of 2020) ICU Medical, Incorporated (NASDAQ: ICUI ) Kala Pharmaceuticals Inc (NASDAQ: KALA ) Mallinckrodt PLC (NYSE: MNK )(reacted to an unfavorable ruling on a patent infringement lawsuit regarding its inhaled nitric oxide product) Neuralstem, Inc. (NASDAQ: CUR ) Novus Therapeutics Inc (NASDAQ: NVUS ) Obalon Therapeutics Inc (NASDAQ: OBLN ) Regeneron Pharmaceuticals Inc (NASDAQ: REGN ) Regenxbio Inc (NASDAQ: RGNX ) Revance Therapeutics Inc (NASDAQ: RVNC )(announced an amended agreement with Mylan NV (NASDAQ: MYL ), …
   The Daily Biotech Pulse: Nuvectra Explores Strategic Options, J&J To Contend Opioid Ruling, Sesen Bio Gets New CFO  2019/08/27 11:29:00 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on Aug. 26) DURECT Corporation (NASDAQ: DRRX ) Stoke Therapeutics Inc (NASDAQ: STOK ) Down In The Dumps (Biotech stocks hitting 52-week lows on Aug. 26) Advaxis, Inc. (NASDAQ: ADXS ) Arbutus Biopharma Corp (NASDAQ: ABUS ) ASLAN PHARMACEU/ADR (NASDAQ: ASLN ) Avanos Medical Inc (NYSE: AVNS ) Cancer Genetics Inc (NASDAQ: CGIX ) Clearside Biomedical Inc (NASDAQ: CLSD ) Elanco Animal Health Inc (NYSE: ELAN )(Bank of America downgraded the shares to Neutral) Neurometrix Inc (NASDAQ: NURO ) Regeneron Pharmaceuticals Inc (NASDAQ: REGN ) Stealth BioTherapeutics Corp (NASDAQ: MITO ) Tetraphase Pharmaceuticals Inc (NASDAQ: TTPH ) Tocagen Inc (NASDAQ: TOCA ) Unity Biotechnology Inc (NASDAQ: UBX ) Zafgen Inc (NASDAQ: ZFGN ) Stocks In Focus Nuvectra To Explore Strategic Options Nuvectra Corp (NASDAQ: NVTR ) announced its decision to explore strategic alternatives to …
   Clearside Stock Plummets After Company Hints At Complete Response Letter For Macular Edema Drug  2019/08/22 15:20:09 Benzinga
Clearside Biomedical Inc (NASDAQ: CLSD ) shares entered penny stock territory Thursday after the company issued an update on what transpired at a meeting with the FDA regarding the new drug application for Xipere. What Happened In a meeting this week, the FDA's Office of Pharmaceutical Quality sought stability data for the triamcinolone acetonide, or TA, suspension produced utilizing an enhanced manufacturing process enacted by the company, Clearside said Thursday. The company submitted an NDA through the 505(b)(2) pathway seeking approval for Xipere, chemically triamcinolone acetonide suprachoroidal injectable suspension. The agency accepted the application Feb. 20 and assigned a PDUFA date of Oct. 19. Xipere is being evaluated for treating patients with macular edema associated … Full story available on Benzinga.com
   Clearside Biomedical, Inc. (CLSD) Reports Q2 Loss, Misses Revenue Estimates  2019/08/08 00:25:10 Zacks Investment Research
Clearside Biomedical, Inc. (CLSD) delivered earnings and revenue surprises of 59.46% and -10.00%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 クリアサイド・バイオメディカル CLSD Clearside Biomedical Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)